Previous 10 | Next 10 |
2024-06-21 09:06:00 ET U.S. stock index futures on Friday pointed to a marginally lower open, a day after Wall Street's rally stalled following another historic milestone. Here are some stocks to watch on Friday: ... Read the full article on Seeking Alpha For further de...
2024-06-20 14:00:04 ET Brian Skorney from Robert W. Baird issued a price target of $80.00 for GILD on 2024-06-20 11:18:00. The adjusted price target was set to $80.00. At the time of the announcement, GILD was trading at $69.21. The overall price target consensus is at $...
2024-06-20 13:00:43 ET Summary Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is proj...
Gilead Sciences, Inc. (NASDAQ: GILD) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 7.74% on the day to $68.04. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in th...
2024-06-20 10:00:20 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Gilead Sciences, Inc. (GILD) Jefferies 2024 Global Healthcare Conference Gilead Sciences: Seriously Undervalued At Peak Pes...
– First Phase 3 HIV Prevention Trial Ever to Show Zero Infections – – Independent Data Monitoring Committee Recommended That Gilead Stop the Blinded Phase of the PURPOSE 1 Trial at Interim Analysis and Offer Open-Label Lenacapavir to All Participants – ...
2024-06-20 08:45:59 ET Palm Beach, FL – June 20, 2024 – Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocar...
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...
NORTHAMPTON, MA / ACCESSWIRE / June 19, 2024 / Gilead Sciences Gilead and Kite Pharma teams raised Pride Month flags at our campuses last week symbolizing our united support for LGBTQ+ communities globally. Our commitment to inclusion and diversity is vital to our mission and will help us cre...
2024-06-18 16:03:19 ET Summary Roche continues to face challenges tied to lackluster revenue and profit outlook, questionable pipeline, and an underperforming diagnostics business. Roche spends aggressively on its pipeline (R&D and M&A) and is more successful than peers in...
News, Short Squeeze, Breakout and More Instantly...
– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Im...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this trans...